A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
Locally Advanced or Metastatic Solid Tumors|Locally Advanced or Metastatic Non-small Cell Lung Cancer
DRUG: XZP-5955 tablets
Maximum tolerated dose (MTD) (Phase I dose escalation), Determine MTD of XZP-5955, 24days following first dose of XZP-5955|Number of patients with adverse events (Phase I dose escalation), Incidence of AE as assessed by CTCAE 5.0, within 30 days from last dose|Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) (Phase I dose expansion and phase II), Per RECIST v1.1 as assessed by BICR, 2 to 3 years after first dose of XZP-5955
Phase I: Area under the concentration versus time curve of XZP-5955 in plasma (AUC), To determine the area under the plasma concentration time curve (AUC) of XZP-5955, Pre-dose, up to 72h after drug on Day 1；pre-dose on day 8, day 15 of cycle 1, , pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3|Phase I: Maximum plasma concentration (Cmax) of XZP-5955, To determine the maximum plasma concentration (Cmax) of XZP-5955, Up to 72 hours post dose of Day 1|Phase I: Oral clearance (CL/F) of XZP-5955, To determine the oral clearance (CL/F) of XZP-5955, Pre-dose, up to 72h after drug on Day 1；pre-dose on day 8, day 15 of cycle 1, pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3|objective response rate (ORR) (Phase I and Phase II), To determine the preliminary objective response rate (ORR) by investigator, 2 to 3 years after first dose of XZP-5955|Progression free survival (PFS) (Phase I and Phase II), To determine the PFS by BICR and investigator, 2 to 3 years after first dose of XZP-5955|Duration of response (DOR) (Phase I and Phase II), To determine the DOR by BICR and investigator, 2 to 3 years after first dose of XZP-5955|Disease control rate (DCR) (Phase I and Phase II), To determine the DOR by BICR and investigator, 2 to 3 years after first dose of XZP-5955|Clinical benefit rate (CBR) (Phase I and Phase II), To determine the CBR by BICR and investigator, 2 to 3 years after first dose of XZP-5955|Time to response (TTR) (Phase I and Phase II), To determine the TTR by BICR and investigator, 2 to 3 years after first dose of XZP-5955|Death of response (DpR) (Phase I and Phase II), To determine the DpR by BICR and investigator, 2 to 3 years after first dose of XZP-5955|Overall survival (OS) (Phase I expansion period and Phase II), To determine the OS, 2 to 3 years after first dose of XZP-5955|Intracranial objective response rate (Phase I expansion period and Phase II), 2 to 3 years after first dose of XZP-5955, To determine the intracranial ORR|Number of patients with adverse events ((Phase I dose expansion and Phase II), Incidence of AE as assessed by CTCAE 5.0, within 30 days from last dose|Pop PK of XZP-5955 and its metabolite (Phase II), To determine the PopPK characteristics of XZP-5955, pre-dose, Tmax on Day1, pre-dose on day 8 of cycle 1, pre-dose on day 1 of Cycle 2, Tmax,ss on Day 1 of cycle 2, pre-dose on day 1 of cycle 3
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion